549. Ensitrelvir for the Treatment of COVID-19 Infection: Evaluation of Taste Disorder and Smell Disorder in the Phase 3 Part of the Phase 2/3 SCORPIO-SR Randomized Controlled Trial

BACKGROUND: Ensitrelvir, a selective SARS-CoV-2 3CL protease inhibitor, is developed as an oral antiviral agent for the treatment of COVID-19 infection. In the Phase 3 part of the randomized SCORPIO-SR trial, the effects of oral ensitrelvir 125 mg and 250 mg on the resolution of taste and smell diso...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuge, Yuko, Sonoyama, Takuhiro, Yotsuyanagi, Hiroshi, Ohmagari, Norio, Doi, Yohei, Yamato, Masaya, Imamura, Takumi, Mukae, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678963/
http://dx.doi.org/10.1093/ofid/ofad500.618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678963/
http://dx.doi.org/10.1093/ofid/ofad500.618

Ejemplares similares